BCAB Relative Valuation
BCAB's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, BCAB is overvalued; if below, it's undervalued.
Historical Valuation
Bioatla Inc (BCAB) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -4.14. The fair price of Bioatla Inc (BCAB) is between -- to -- according to relative valuation methord.
Relative Value
Fair Zone
-----
Current Price：0.40
Fair
-0.56
PE
1Y
3Y
5Y
0.00
EV/EBITDA
Bioatla Inc. (BCAB) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is -2.62. The thresholds are as follows: Strongly Undervalued below -14.33, Undervalued between -14.33 and -8.47, Fairly Valued between 3.24 and -8.47, Overvalued between 3.24 and 9.09, and Strongly Overvalued above 9.09. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.
-0.48
EV/EBIT
Bioatla Inc. (BCAB) has a current EV/EBIT of -0.48. The 5-year average EV/EBIT is -2.64. The thresholds are as follows: Strongly Undervalued below -14.45, Undervalued between -14.45 and -8.55, Fairly Valued between 3.26 and -8.55, Overvalued between 3.26 and 9.17, and Strongly Overvalued above 9.17. The current Forward EV/EBIT of -0.48 falls within the Historic Trend Line -Fairly Valued range.
0.00
PS
Bioatla Inc. (BCAB) has a current PS of 0.00. The 5-year average PS is 74.39. The thresholds are as follows: Strongly Undervalued below -145.12, Undervalued between -145.12 and -35.36, Fairly Valued between 184.15 and -35.36, Overvalued between 184.15 and 293.91, and Strongly Overvalued above 293.91. The current Forward PS of 0.00 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/OCF
Bioatla Inc. (BCAB) has a current P/OCF of 0.00. The 5-year average P/OCF is -4.86. The thresholds are as follows: Strongly Undervalued below -21.73, Undervalued between -21.73 and -13.30, Fairly Valued between 3.57 and -13.30, Overvalued between 3.57 and 12.00, and Strongly Overvalued above 12.00. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/FCF
Bioatla Inc. (BCAB) has a current P/FCF of 0.00. The 5-year average P/FCF is -4.78. The thresholds are as follows: Strongly Undervalued below -20.99, Undervalued between -20.99 and -12.89, Fairly Valued between 3.32 and -12.89, Overvalued between 3.32 and 11.43, and Strongly Overvalued above 11.43. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
Bioatla Inc (BCAB) has a current Price-to-Book (P/B) ratio of -1.01. Compared to its 3-year average P/B ratio of 4.12 , the current P/B ratio is approximately -124.42% higher. Relative to its 5-year average P/B ratio of 4.12, the current P/B ratio is about -124.40% higher. Bioatla Inc (BCAB) has a Forward Free Cash Flow (FCF) yield of approximately -180.97%. Compared to its 3-year average FCF yield of -142.49%, the current FCF yield is approximately 27.00% lower. Relative to its 5-year average FCF yield of -93.71% , the current FCF yield is about 93.11% lower.
-1.01
P/B
Median3y
4.12
Median5y
4.12
-180.97
FCF Yield
Median3y
-142.49
Median5y
-93.71
Competitors Valuation Multiple
The average P/S ratio for BCAB's competitors is 52.79, providing a benchmark for relative valuation. Bioatla Inc Corp (BCAB) exhibits a P/S ratio of 0.00, which is -100% above the industry average. Given its robust revenue growth of -100.00%, this premium appears unsustainable.
Performance Decomposition
1Y
3Y
5Y
Market capitalization of BCAB increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of BCAB in the past 1 year is driven by Unknown.
People Also Watch
CTXR
Citius Pharmaceuticals Inc
0.9USD
-2.70%
COCH
Envoy Medical Inc
0.691USD
-0.43%
SOWG
Sow Good Inc
0.5USD
-5.31%
BGI
Birks Group Inc
0.9042USD
0.44%
HVT.A
Haverty Furniture Companies Inc
23.14USD
0.00%
CGTX
Cognition Therapeutics Inc
1.43USD
-3.38%
FOXX
Foxx Development Holdings Inc
4.22USD
-0.71%
AXIL
AXIL Brands Inc
7.13USD
15.56%
NSYS
Nortech Systems Inc
7.65USD
-1.80%
PMEC
Primech Holdings Ltd
1.05USD
6.06%
Frequently Asked Questions
Is Bioatla Inc (BCAB) currently overvalued or undervalued?
Bioatla Inc (BCAB) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -4.14. The fair price of Bioatla Inc (BCAB) is between to according to relative valuation methord.
What is Bioatla Inc (BCAB) fair value?
BCAB's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Bioatla Inc (BCAB) is between to according to relative valuation methord.
How does BCAB's valuation metrics compare to the industry average?
The average P/S ratio for BCAB's competitors is 52.79, providing a benchmark for relative valuation. Bioatla Inc Corp (BCAB) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of -100.00%, this premium appears unsustainable.
What is the current P/B ratio for Bioatla Inc (BCAB) as of Jan 08 2026?
As of Jan 08 2026, Bioatla Inc (BCAB) has a P/B ratio of -1.01. This indicates that the market values BCAB at -1.01 times its book value.
What is the current FCF Yield for Bioatla Inc (BCAB) as of Jan 08 2026?
As of Jan 08 2026, Bioatla Inc (BCAB) has a FCF Yield of -180.97%. This means that for every dollar of Bioatla Inc’s market capitalization, the company generates -180.97 cents in free cash flow.
What is the current Forward P/E ratio for Bioatla Inc (BCAB) as of Jan 08 2026?
As of Jan 08 2026, Bioatla Inc (BCAB) has a Forward P/E ratio of -0.56. This means the market is willing to pay $-0.56 for every dollar of Bioatla Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Bioatla Inc (BCAB) as of Jan 08 2026?
As of Jan 08 2026, Bioatla Inc (BCAB) has a Forward P/S ratio of 0.00. This means the market is valuing BCAB at $0.00 for every dollar of expected revenue over the next 12 months.